甲氨蝶呤二钠盐（CAS 7413-34-5）：分子式 C20H20N8Na2O5、分子量 498.4；类别 医药中间体及原料药。
| CAS号 | 7413-34-5 |
|---|---|
| 分子式 | C20H20N8Na2O5 |
| 分子量 | 498.4 |
| 应用领域 | Uses: Methotrexate is indicated in the treatment of gestational choriocarcinoma、chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia、methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer、epidermoid cancers of the head and neck、advanced mycosis fungoides (cutaneous T cell lymphoma)、and lung cancer、particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Methotrexate is indicated in the symptomatic control of severe、recalcitrant、disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe、active rheumatoid arthritis (ACR criteria)、or children with active polyarticular-course juvenile rheumatoid arthritis. |
| 类别 | 医药原料 |
登记用途：Uses: Methotrexate is indicated in the treatment of gestational choriocarcinoma、chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia、methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer、epidermoid cancers of the head and neck、advanced mycosis fungoides (cutaneous T cell lymphoma)、and lung cancer、particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Methotrexate is indicated in the symptomatic control of severe、recalcitrant、disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe、active rheumatoid arthritis (ACR criteria)、or children with active polyarticular-course juvenile rheumatoid arthritis.。
甲氨蝶呤二钠盐 是一种医药中间体或原料药类化合物，登记 CAS 号为 7413-34-5，分子式 C20H20N8Na2O5（分子量 498.4），归属于医药中间体及原料药大类化工原料。
登记 CAS 号：7413-34-5
其分子式 C20H20N8Na2O5 由 20 个碳、20 个氢、8 个氮、2 个钠、5 个氧 组成。
别名/同义词：甲氨蝶呤二钠盐 · Methotrexate disodium salt
所属分类：医药中间体及原料药
甲氨蝶呤二钠盐 的 CAS 登记号为 7413-34-5。
分子式 C20H20N8Na2O5，分子量 498.4。
别名/同义词：甲氨蝶呤二钠盐、Methotrexate disodium salt。
登记用途：Uses: Methotrexate is indicated in the treatment of gestational choriocarcinoma、chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia、methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer、epidermoid cancers of the head and neck、advanced mycosis fungoides (cutaneous T cell lymphoma)、and lung cancer、particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas. Methotrexate is indicated in the symptomatic control of severe、recalcitrant、disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe、active rheumatoid arthritis (ACR criteria)、or children with active polyarticular-course juvenile rheumatoid arthritis.。
所属分类：医药原料。
甲氨蝶呤二钠盐（CAS 7413-34-5）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 7413-34-5 |
|---|---|
| PubChem CID | 11329481 |
| Molecular formula | C20H20N8Na2O5 |
| Molecular weight | 498.14 g/mol |
| IUPAC name | disodium;(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioate |
| InChIKey | DASQOOZCTWOQPA-GXKRWWSZSA-L |
| UNII (FDA) | 3IG1E710ZN |
| ChEBI ID | CHEBI:50679 |
| Molecular Weight | 498.4 |
|---|---|
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 498.13520433 |
| Monoisotopic Mass | 498.13520433 |
| Topological Polar Surface Area | 216 |
| Heavy Atom Count | 35 |
Methotrexate disodium salt; 7413-34-5; METHOTREXATE SODIUM; Sodium methotrexate; Disodium methotrexate; Abitrexate; Trexall; Methotrexate Lpf; Folex Pfs; Mexate-Aq Preserved; Mexate-Aq; Methotrexate sodium salt; Methotrexate, Sodium Salt; Methotrexate (as disodium); ADX-2191 SODIUM; Methotrexate Preservative Free
| Reported hazard statements | H301 (100%), H311 (98.1%), H315 (100%), H319 (100%), H331 (98.1%), H335 (98.1%), H340 (98.1%), H360 (100%) |
|---|
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
H311 (98.1%): Toxic in contact with skin [Danger Acute toxicity, dermal]
Methotrexate disodium salt is identified by CAS 7413-34-5, molecular formula C20H20N8Na2O5 and molecular weight 498.14 g/mol. UNII 3IG1E710ZN; ChEBI 50679; InChIKey DASQOOZCTWOQPA-GXKRWWSZSA-L.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Methotrexate disodium salt